IMP3 Expression As a Potential Tumour Marker in High-Risk Localisations of Cutaneous Squamous Cell Carcinoma: IMP3 in Metastatic CSCC

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Aug 26

PMID 37627115

Authors

Maurice Klein

Merle Wefers

Christian Hallermann

Henrike J Fischer

Frank Holzle

Kai Wermker

Affiliations

Soon will be listed here.

Abstract

Background: High IMP3 expression is correlated with a worse outcome. Until now, there have been no data about IMP3 expression and clinical outcome for high-risk localisation of squamous cell carcinoma of the skin (cSCC).

Methods: One-hundred twenty-two patients with cSCC of the lip and ear were included, and IMP3 expression in the tumours was immunohistochemically assessed in different evaluation approaches. Subsequently, subgroups were analysed in a matched pair approach and correlated with clinical pathologic parameters. In the following, different IMP3 analysis methods were tested for clinical suitability.

Results: We found a significant correlation between IMP3 expression and risk for lymph node metastasis, local relapse, and progression-free survival.

Conclusions: On basis of our data, we suggest a prognostic benefit cutoff value for high (>50%) and low (<50%) IMP3 expression. Thus, IMP3 expression has a high scientific potential for further studies and could potentially be used as a prognostic marker in diagnostic and therapeutic decision-making.

Citing Articles

Biomarkers of lymph node metastasis in colorectal cancer: update.

Zhu X, Lin S, Xie J, Wang L, Zhang L, Xu L Front Oncol. 2024; 14:1409627.

PMID: 39328205 PMC: 11424378. DOI: 10.3389/fonc.2024.1409627.

Biomarkers of Tumor Metastasis and Invasiveness.

Pouliquen D, Nunez Gonzalez C Cancers (Basel). 2023; 15(20).

PMID: 37894367 PMC: 10605113. DOI: 10.3390/cancers15205000.

References

Leiter U, Heppt M, Steeb T, Amaral T, Bauer A, Becker J . S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) - short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease. J Dtsch Dermatol Ges. 2020; 18(4):400-413. DOI: 10.1111/ddg.14072. View

Li H, Han J, Huang Z, Wang L, Chen W, Shen X . IMP3 is a novel biomarker to predict metastasis and prognosis of tongue squamous cell carcinoma. J Craniofac Surg. 2011; 22(6):2022-5. DOI: 10.1097/SCS.0b013e3182319750. View

Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H . Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. Int J Cancer. 2014; 135(7):1596-604. DOI: 10.1002/ijc.28808. View

Klein M, Wermker K, Hallermann C, Pannier F, Holzle F, Modabber A . Immune checkpoint analysis in lip cancer. J Craniomaxillofac Surg. 2021; 49(10):950-958. DOI: 10.1016/j.jcms.2021.05.007. View

Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y . Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 2012; 10:141. PMC: 3403921. DOI: 10.1186/1479-5876-10-141. View

Han A, Kuan E, Mallen-St Clair J, Alonso J, Arshi A, St John M . Epidemiology of Squamous Cell Carcinoma of the Lip in the United States: A Population-Based Cohort Analysis. JAMA Otolaryngol Head Neck Surg. 2016; 142(12):1216-1223. DOI: 10.1001/jamaoto.2016.3455. View

Kanzaki A, Kudo M, Ansai S, Peng W, Ishino K, Yamamoto T . Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma. Int J Oncol. 2016; 48(3):1007-15. PMC: 4750532. DOI: 10.3892/ijo.2016.3323. View

Takizawa K, Yamamoto H, Taguchi K, Ohno S, Tokunaga E, Yamashita N . Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast. Hum Pathol. 2016; 55:30-8. DOI: 10.1016/j.humpath.2016.04.007. View

Schmults C, Karia P, Carter J, Han J, Qureshi A . Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013; 149(5):541-7. DOI: 10.1001/jamadermatol.2013.2139. View

10.

Burdelski C, Jakani-Karimi N, Jacobsen F, Moller-Koop C, Minner S, Simon R . IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. Oncol Rep. 2017; 39(1):3-12. PMC: 5783598. DOI: 10.3892/or.2017.6072. View

11.

Bell J, Wachter K, Muhleck B, Pazaitis N, Kohn M, Lederer M . Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?. Cell Mol Life Sci. 2012; 70(15):2657-75. PMC: 3708292. DOI: 10.1007/s00018-012-1186-z. View

12.

Ohashi R, Sangen M, Namimatsu S, Yanagihara K, Yamashita K, Sakatani T . Prognostic value of IMP3 expression as a determinant of chemosensitivity in triple-negative breast cancer. Pathol Res Pract. 2017; 213(9):1160-1165. DOI: 10.1016/j.prp.2017.07.002. View

13.

Chen L, Xie Y, Li X, Gu L, Gao Y, Tang L . Prognostic value of high IMP3 expression in solid tumors: a meta-analysis. Onco Targets Ther. 2017; 10:2849-2863. PMC: 5476767. DOI: 10.2147/OTT.S128810. View

14.

Wermker K, Belok F, Schipmann S, Klein M, Schulze H, Hallermann C . Prediction model for lymph node metastasis and recommendations for elective neck dissection in lip cancer. J Craniomaxillofac Surg. 2015; 43(4):545-52. DOI: 10.1016/j.jcms.2015.02.002. View

15.

Soddu S, Di Felice E, Cabras S, Castellanos M, Atzori L, Faa G . IMP-3 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study. Eur J Histochem. 2013; 57(1):e6. PMC: 3683613. DOI: 10.4081/ejh.2013.e6. View

16.

Alam M, Ratner D . Cutaneous squamous-cell carcinoma. N Engl J Med. 2001; 344(13):975-83. DOI: 10.1056/NEJM200103293441306. View

17.

Liao B, Hu Y, Brewer G . RNA-binding protein insulin-like growth factor mRNA-binding protein 3 (IMP-3) promotes cell survival via insulin-like growth factor II signaling after ionizing radiation. J Biol Chem. 2011; 286(36):31145-52. PMC: 3173139. DOI: 10.1074/jbc.M111.263913. View

18.

Czerninski R, Zini A, Sgan-Cohen H . Lip cancer: incidence, trends, histology and survival: 1970-2006. Br J Dermatol. 2010; 162(5):1103-9. DOI: 10.1111/j.1365-2133.2010.09698.x. View

19.

Lin C, Chen S, Jeng Y, Yeh C, Chou H, Deng Y . Insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor formation and invasion and predicts poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med. 2013; 40(9):699-705. DOI: 10.1111/j.1600-0714.2011.01019.x. View

20.

Lu D, Yang X, Jiang N, Woda B, Liu Q, Dresser K . IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol. 2011; 35(11):1638-45. DOI: 10.1097/PAS.0b013e31823272d4. View